Many pharma QC labs trust their LabWare setup because “we’ve never had a serious finding.”
However, regulators do not evaluate historical comfort. Instead, they assess the current control state of computerized systems.
In this case, a German pharmaceutical company approached Zamann Pharma Support to ensure that their LabWare environment and related CSV documentation fully complied with FDA regulations and GAMP guidelines.
Over time, the system had evolved. LabWare had been patched, extended, and integrated with new templates and interfaces. Meanwhile, documentation, role concepts, and audit trail reviews did not always keep pace.
Consequently, risks around Part 11 compliance, data integrity, and system control increased without being clearly visible.
This case study presents how a structured GAP Assessment and CAPA-driven approach was used to evaluate and strengthen compliance readiness in a LabWare environment.
Our team supports the planning, execution, and maintenance of qualification and validation activities, including IQ, OQ, and PQ, to keep GMP-regulated systems compliant and under control.
Inspectors do not accept “system is validated” as evidence by itself. They expect to see a traceable control chain inside LabWare. Therefore, you must demonstrate that every critical data change is captured in a complete, tamper-evident audit trail and directly linked to user identity, timestamp, and original values. In addition, you need to show that audit trail reviews are embedded in routine batch or sample release workflows—not performed ad hoc during inspections.
Moreover, regulators typically challenge whether audit trail data is actionable, not just stored. So you should be able to retrieve changes per sample, per batch, or per method without manual database extraction. If you cannot do this within minutes, it signals a design gap rather than a documentation issue. Ultimately, trust is not declared; it is demonstrated through system design and operational evidence working together.
The most frequent failure is ineffective segregation of duties combined with weak role design. In many systems, users accumulate permissions over time, which creates a hidden risk: analysts may end up executing, reviewing, and approving the same data set. This directly contradicts Part 11 expectations and EU Annex 11 principles.
In addition, auditors often discover that roles are not mapped to documented responsibilities. Instead, they are defined technically rather than functionally. As a result, the system allows actions that SOPs do not clearly govern. Furthermore, electronic signatures may technically exist, but they lack enforced meaning—so approvals become procedural rather than controlled decisions.
To avoid this, LabWare must enforce least privilege by design, and QA must formally approve the role matrix. Otherwise, segregation of duties becomes theoretical instead of enforceable in practice.
Audit trail failures usually occur not at the technical level but at the process design level. Even though LabWare often captures audit events correctly, organizations fail to define how, when, and by whom these records are reviewed. Consequently, audit trails exist only as stored data rather than active compliance controls.
Furthermore, many QC environments lack structured review paths. For example, analysts may review results without checking underlying audit changes, while QA performs periodic reviews without a defined sampling strategy. This creates gaps that inspectors immediately identify.
In addition, audit trail outputs are often not usable in real workflows. If users must extract raw logs or rely on IT support, review becomes inconsistent and non-repeatable. Therefore, effective compliance requires designing audit trail usability into LabWare not adding it after implementation. When review processes are embedded into batch release and QA oversight, audit trails transform from a regulatory burden into a controlled decision-support mechanism.
